CMS continues to focus on site-neutral payment policies and keeping payments down for 340B-acquired drugs in the 2021 OPPS proposed rule, released in early August.
This week’s Medicare updates include the 2021 Quality Payment Program proposed rule, new FAQs regarding COVID-19 topics, the October update to the clinical laboratory fee schedule, and more!
Facing the unprecedented COVID-19 public health emergency, CMS released the 2021 OPPS proposed rule later than ever before, with the agency generally reinforcing its recent focus on site-neutral payment policies, lowering reimbursement for drugs purchased under the 340B program, and adding more services to the list of prior authorization.
Judith L. Kares, JD, writes about the unique coverage, billing, and payment rules that apply to these blood products and related services under Part B.
In response to the novel coronavirus (COVID-19) public health emergency, CMS has expanded patient access to telehealth services, allowing beneficiaries to receive a wide range of services without having to visit a healthcare facility.
